Abstract:BACKGROUND & OBJECTIVE:Primary central nervous system (CNS) germ cell tumors (GCTs) are rare malignant neoplasms with various histological types. Excluding pure germinoma and mature teratoma, other types carry a poor prognosis. Previous investigations focused on combined modality treatment including chemotherapy to improve survival. This study was to analyze the efficacy and toxicity of chemotherapy combined with surgery and/or radiotherapy on CNS GCTs.METHODS:A total of 23 patients with CNS GCTs were treated in Cancer Center of Sun Yat-sen University from May 2002 to Jun. 2006. The median age at diagnosis was 16 years. Alpha-fetoprotein (AFP) and/or beta-human chorionic gonadotropin (beta-HCG) levels were elevated in 19 patients (82.6%). All patients were treated with chemotherapy of PEB regimen combined with surgery and/or radiotherapy. PEB regimen was administered every 3 weeks with 20 mg/m(2) cisplatin (DDP) at Days 1-5 or 80-100 mg/m(2) at Day 1, 60-100 mg/m(2) etoposide (VP-16) or teniposide (VM-26) at Days 1-5, 10 mg/m(2) bleomycin (BLM) at Days 1 and 5.RESULTS:Of the 23 patients, 17 newly diagnosed patients received induction chemotherapy followed by radiotherapy or surgery/radiotherapy followed by adjuvant chemotherapy; 6 recurrent patients received salvage chemotherapy, of which 3 patients with disseminated tumor received salvage chemotherapy followed by craniospinal irradiation. The 23 patients completed a total of 61 cycles of PEB regimen with a median of 3 cycles. Chemotherapy alone gained a response rate of 87.0% and a complete remission rate of 30.4%. Craniospinal irradiation was performed in 14 patients and focal irradiation in 8 patients. One patient did not receive irradiation. Incomplete tumor resection or biopsy was performed in 13 patients. Fourteen patients (60.9%) were alive without evidence of diseases after combined modality treatment. With a median follow-up of 24 months, the 2-year survival rate was 67.4%. Main adverse events were late irradiation injury including aplastic anemia and hypothalamus syndrome (1 case), irradiation encephalopathy (1 case), and hypopituitarism (2 cases).CONCLUSIONS:The combined modality treatment including PEB regimen is highly effective in treating CNS GCTs patients, especially in the patients with elevated tumor markers. However, the long-term toxicities which related with craniospinal irradiation should not be ignored.

Integrated Analysis of Serum Lymphocytes Develops a Nomogram for Predicting Prognosis of Intracranial Germ Cell Tumors to Chemo-Radiotherapy

Dynamic Analysis of Immune Status in Patients with Intracranial Germ Cell Tumor and Establishment of an Immune Risk Prognostic Model

IMMU-49. DYNAMIC CHANGES AND PROGNOSTIC VALUE OF PERIPHERAL BLOOD LYMPHOCYTE SUBSETS IN INTRACRANIAL GERM CELL TUMORS

Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

Article Full Title: Outcomes of Patients with Intracranial Germ Cell Tumour with Choriocarcinoma Element or Β-Hcg Level Higher Than 500 IU/L under Radiotherapy-Based Treatments Short Running Title: Intracranial Choriocarcinoma

Outcomes of patients with intracranial germ cell tumour with choriocarcinoma element or β-HCG level higher than 500 IU/L under radiotherapy-based treatments

Peripheral Blood CD8 + CD28 + T Cells as an Independent Predictor of Treatment Response and Survival After Concurrent Chemoradiotherapy in Pediatric High-Grade Glioma Patients

RARE-20. ANALYSIS OF CLINICAL FEATURES ON DEATH FROM INTRACRANIAL GERM CELL TUMORS (GCTS): ARETROSPECTIVE COHORT STUDY

Individualized treatment of intracranial germ cell tumors

A Novel Immune Gene-Related Prognostic Score Predicts Survival and Immunotherapy Response in Glioma

Treatment of primary intracranial germ cell tumors: Single center experience with 42 clinically diagnosed cases.

CTNI-62. CLINICAL FEATURES AND PROGNOSTIC FACTORS OF NONGERMINOMATOUS GERM CELL TUMORS IN 111 CONSECUTIVE PATIENTS IN A SINGLE INSTITUTION: IMPACT OF IRRADIATION AND CHEMOTHERAPY CYCLES ON SURVIVAL

Epid-36. Clinical Features Of 614 Primary Intracranial Germ Cell Tumors: An 15-Year Experience Of A Single Center In China

Comparative observational study of serum neoplastic biomarker and immunohistochemistry in 28 cases of intracranial germ cell tumors

Treatment outcomes and risk factors of patients with intracranial germ cell tumour with choriocarcinoma element or β-HCG level higher than 500 IU/L

Grading System for Diagnosis and Treatment of Intracranial Nongerminomatous Malignant Germ Cell Tumors

CTNI-60. NEOAJUVANT CHEMOTHERAPY FOLLOWED BY CRANIOSPINAL IRRADIATION FOR INTRACRANIAL NGGCTS: CLINICAL OUTCOMES AND AGE-STRATIFIED TOXICITIES IN A COHORT OF 111 PATIENTS

[Treatment Outcome of Primary Central Nervous System Germ Cell Tumors after Combined Therapy: a Report of 23 Cases].

Development and validation of a nomogram to predict overall survival and cancer-specific survival in patients with primary intracranial malignant lymphoma: A Retrospective study based on the SEER database

Clinical outcome and prognostic factors for immunotherapy-based treatments in patients with platinum-refractory germ cell tumor

Cumulative Scoring Systems and Nomograms for Predicating Survival in Patients With Glioblastomas: A Study Based on Peripheral Inflammatory Markers